Literature DB >> 21609370

Differences in phosphatidylcholine and bile acids in bile from Egyptian and UK patients with and without cholangiocarcinoma.

Mohamed S Hashim Abdalla1, Simon D Taylor-Robinson, Amar W Sharif, Horace R T Williams, Mary M E Crossey, Gamal A Badra, Andrew V Thillainayagam, Devinder S Bansi, Howard C Thomas, Imam A Waked, Shahid A Khan.   

Abstract

BACKGROUND: Cholangiocarcinoma (CC) is a fatal malignancy, the incidence of which is increasing worldwide, with substantial regional variation. Current diagnostic techniques to distinguish benign from malignant biliary disease are unsatisfactory. Metabolic profiling of bile may help to differentiate benign from malignant disease. No previous studies have compared the metabolic profiles of bile from two geographically and racially distinct groups of CC patients.
OBJECTIVES: This study aimed to compare metabolic profiles of bile, using in vitro proton magnetic resonance spectroscopy, from CC patients from Egypt and the UK, and from patients with CC and patients with non-malignant biliary disease.
METHODS: A total of 29 bile samples, collected at cholangiography, were analysed using an 11.7-T system. Samples were from eight CC patients in either Egypt (n = 4) or the UK (n = 4) and 21 patients with benign biliary disease (choledocholithiasis [n = 8], sphincter of Oddi dysfunction [n = 8], primary sclerosing cholangitis [n = 5]).
RESULTS: Bile phosphatidylcholine (PtC) was significantly reduced in CC patients. Egyptian CC patients had significantly lower biliary PtC levels compared with UK patients. Taurine- and glycine-conjugated bile acids (H-26 and H-25 protons, respectively) were significantly elevated in bile from patients with CC compared with bile from patients with benign diseases (P = 0.013 and P < 0.01, respectively).
CONCLUSIONS: Biliary PtC levels potentially differentiate CC from benign biliary disease. Reduced biliary PtC in Egyptian compared with UK patients may reflect underlying carcinogenic mechanisms.
© 2011 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21609370      PMCID: PMC3103094          DOI: 10.1111/j.1477-2574.2011.00296.x

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  23 in total

1.  Proton magnetic resonance assay of total and taurine-conjugated bile acids in bile.

Authors:  H Ishikawa; T Nakashima; K Inaba; H Mitsuyoshi; Y Nakajima; Y Sakamoto; T Okanoue; K Kashima; Y Seo
Journal:  J Lipid Res       Date:  1999-10       Impact factor: 5.922

2.  A novel role for the Bcl-2 protein family: specific suppression of the RAD51 recombination pathway.

Authors:  Y Saintigny; A Dumay; S Lambert; B S Lopez
Journal:  EMBO J       Date:  2001-05-15       Impact factor: 11.598

Review 3.  Oxidative DNA damage: mechanisms, mutation, and disease.

Authors:  Marcus S Cooke; Mark D Evans; Miral Dizdaroglu; Joseph Lunec
Journal:  FASEB J       Date:  2003-07       Impact factor: 5.191

Review 4.  The regulation and cellular functions of phosphatidylcholine hydrolysis.

Authors:  M M Billah; J C Anthes
Journal:  Biochem J       Date:  1990-07-15       Impact factor: 3.857

5.  MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine.

Authors:  A van Helvoort; A J Smith; H Sprong; I Fritzsche; A H Schinkel; P Borst; G van Meer
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

Review 6.  MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes.

Authors:  Michael Trauner; Peter Fickert; Martin Wagner
Journal:  Semin Liver Dis       Date:  2007-02       Impact factor: 6.115

Review 7.  The molecular pathogenesis of cholangiocarcinoma.

Authors:  Eric P Berthiaume; Jack Wands
Journal:  Semin Liver Dis       Date:  2004-05       Impact factor: 6.115

8.  Changing international trends in mortality rates for liver, biliary and pancreatic tumours.

Authors:  Shahid A Khan; Simon D Taylor-Robinson; Mireille B Toledano; Angus Beck; Paul Elliott; Howard C Thomas
Journal:  J Hepatol       Date:  2002-12       Impact factor: 25.083

9.  Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma.

Authors:  S A Khan; M B Toledano; S D Taylor-Robinson
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

10.  A new NMR-based metabolomics approach for the diagnosis of biliary tract cancer.

Authors:  He Wen; Sung Soo Yoo; Jinho Kang; Hee Goo Kim; Jin-Seok Park; Seok Jeong; Jung Il Lee; Hyuk Nam Kwon; Sunmi Kang; Don-Haeng Lee; Sunghyouk Park
Journal:  J Hepatol       Date:  2009-11-27       Impact factor: 25.083

View more
  12 in total

1.  Biliary phosphatidylcholine and lysophosphatidylcholine profiles in sclerosing cholangitis.

Authors:  Annika Gauss; Robert Ehehalt; Wolf-Dieter Lehmann; Gerhard Erben; Karl-Heinz Weiss; Yvonne Schaefer; Petra Kloeters-Plachky; Adolf Stiehl; Wolfgang Stremmel; Peter Sauer; Daniel Nils Gotthardt
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

Review 2.  Diagnosis Biomarkers of Cholangiocarcinoma in Human Bile: An Evidence-Based Study.

Authors:  Fang Bao; Jiayue Liu; Haiyang Chen; Lu Miao; Zhaochao Xu; Guixin Zhang
Journal:  Cancers (Basel)       Date:  2022-08-13       Impact factor: 6.575

Review 3.  The metabolomic window into hepatobiliary disease.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  J Hepatol       Date:  2013-05-25       Impact factor: 25.083

Review 4.  Current and future roles of mucins in cholangiocarcinoma-recent evidences for a possible interplay with bile acids.

Authors:  Elisa Danese; Andrea Ruzzenente; Martina Montagnana; Patricia Marie-Jeanne Lievens
Journal:  Ann Transl Med       Date:  2018-09

5.  Characterisation of the Serum Metabolic Signature of Cholangiocarcinoma in a United Kingdom Cohort.

Authors:  Munirah Alsaleh; Zoe Leftley; Thomas A Barbera; Larry K Koomson; Abigail Zabron; Mary M E Crossey; Helen L Reeves; Matthew Cramp; Stephen Ryder; Shaun Greer; Martin Prince; Paiboon Sithithaworn; Mohamed Shariff; Narong Khuntikeo; Watcharin Loilome; Puangrat Yongvanit; Yi-Liang Shen; I Jane Cox; Roger Williams; Christopher A Wadsworth; Elaine Holmes; Kathryn Nash; Simon D Taylor-Robinson
Journal:  J Clin Exp Hepatol       Date:  2019-06-15

6.  Biliary Microbiota and Bile Acid Composition in Cholelithiasis.

Authors:  Vyacheslav A Petrov; María A Fernández-Peralbo; Rico Derks; Elena M Knyazeva; Nikolay V Merzlikin; Alexey E Sazonov; Oleg A Mayboroda; Irina V Saltykova
Journal:  Biomed Res Int       Date:  2020-07-01       Impact factor: 3.411

Review 7.  The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer.

Authors:  Abigail Zabron; Robert J Edwards; Shahid A Khan
Journal:  Dis Model Mech       Date:  2013-03       Impact factor: 5.758

8.  Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2.

Authors:  Runping Liu; Renping Zhao; Xiqiao Zhou; Xiuyin Liang; Deanna J W Campbell; Xiaoxuan Zhang; Luyong Zhang; Ruihua Shi; Guangji Wang; William M Pandak; Alphonse E Sirica; Phillip B Hylemon; Huiping Zhou
Journal:  Hepatology       Date:  2014-07-28       Impact factor: 17.425

9.  Comprehensive analysis of transcriptome and metabolome analysis in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma.

Authors:  Yoshiki Murakami; Shoji Kubo; Akihiro Tamori; Saori Itami; Etsushi Kawamura; Keiko Iwaisako; Kazuo Ikeda; Norifumi Kawada; Takahiro Ochiya; Y-h Taguchi
Journal:  Sci Rep       Date:  2015-11-05       Impact factor: 4.379

10.  Discovery of glycocholic acid and taurochenodeoxycholic acid as phenotypic biomarkers in cholangiocarcinoma.

Authors:  Won-Suk Song; Hae-Min Park; Jung Min Ha; Sung Gyu Shin; Han-Gyu Park; Joonwon Kim; Tianzi Zhang; Da-Hee Ahn; Sung-Min Kim; Yung-Hun Yang; Jae Hyun Jeong; Ashleigh B Theberge; Byung-Gee Kim; Jong Kyun Lee; Yun-Gon Kim
Journal:  Sci Rep       Date:  2018-07-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.